Publication in refereed journal
香港中文大学研究人员 ( 现职)
| 李锦滔教授 |
| 黎嘉能教授 (内科及药物治疗学系) |
| 林伟基教授 (化学病理学系) |
| 雷兆辉教授 (赛马会公共卫生及基层医疗学院) |
全文
| 没有全文档案提供 |
引用次数
Web of Sciencehttp://aims.cuhk.edu.hk/converis/portal/Publication/25WOS source URL
其它资讯
摘要A possible interaction between fluvastatin, a new HMG CoA reductase inhibitor, and cyclosporin A (CsA) was studied in 16 stable renal transplant patients with dyslipoproteinemia despite dietary control. They entered a 12-week study period: 4-week baseline, 4-week placebo and 4-week fluvastatin treatment (20 mg daily). Weekly trough whole blood CsA concentrations were measured by monoclonal antibody immunoassay. Serial renal and liver function tests and creatine phosphokinase (CPK) were monitored. The mean trough levels of CsA during fluvastatin treatment were 115.6 mu g/l compared with 114.3 mu g/l and 113.3 mu g/l in the baseline and placebo period, respectively. Apart from a small decrease in serum albumin level (from a mean of 38.6 g/l to 37.9 g/l), there were no significant changes in renal and liver functions or CPK levels. No adverse effects were reported. Fluvastatin (20 mg daily) may be used safely without extra monitoring of blood CsA concentrations in renal transplant patients.
着者LI PKT, MAK TWL, WANG AYM, LEE YT, LEUNG CB, LUI SF, LAM CWK, LAI KN
期刊名称International Journal of Clinical Pharmacology and Therapeutics
出版年份1995
月份4
日期1
卷号33
期次4
出版社DUSTRI-VERLAG DR KARL FEISTLE
页次246 - 248
国际标準期刊号0946-1965
语言英式英语
关键词CYCLOSPORINE A; FLUVASTATIN; INTERACTION; RENAL TRANSPLANT
Web of Science 学科类别Pharmacology & Pharmacy; PHARMACOLOGY & PHARMACY
